Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: Dose dependent tumor eradication and generation of protective immunity

Journal of Urology

Volumn 171, Issue 3, 2004, Pages 1330-1335

  O'Donnell, Michael A ^a   Luo, Yi ^a   Hunter, Sharon E ^b   Chen, Xiaohong ^a   Hayes, Lori L ^b   Clinton, Steven K ^c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b PFIZER INC   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Bladder; Carcinoma, transitional cell; Immunotherapy; Interleukin 12; Mice

Indexed keywords

INTERLEUKIN 12;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

EID: 1542267863     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000109742.88380.a2     Document Type: Article

References (21)

1. Jemal, A., Murry, T., Samuels, A., Ghafoor, A., Ward, E. and Thun, M. J.: Cancer statistics, 2003. CA Cancer J Clin, 53: 5, 2003
2. Silvester, R. J., Van der Meijden, A. P. M. and Lamm, D. L.: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol, 168: 1964, 2002
3. Bohle, A. and Brandau, S.: Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol, 170: 964, 2003
4. O'Donnell, M. A., Luo, Y., Chen, X., Svilvasi, A., Hunter, S. E. and Clinton, S. K.: Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guerin. J Immunol, 163: 4246, 1999
5. Saint, F., Patard, J. J., Maille, P., Soyeux, P., Hoznek, A., Salomon, L. et al: Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol, 167: 364, 2002
6. Columbo, M. P. and Trinchieri, G.: Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev, 13: 155, 2002
7. Brunda, M. J., Luistro, L., Rumennik, L., Wright, R. B., Dvorozniak, M., Aglione, A. et al: Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother Pharmacol, suppl., 38: S16, 1996
8. Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J. et al: Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol, 153: 1697, 1994
9. Hunter, S. E., Waldburger, K. E., Thibodeaux, D. K., Schaub, R. G., Goldman, S. J. and Leonard, J. P.: Immunoregulation by interleukin-12 in MB49.1 tumor-bearing mice: cellular and cytokine-mediated effector mechanisms. Eur J Immunol, 27: 3438, 1997
10. Tahara, H., Zitvogel, L., Storkus, W. J., Zeh, H. J., 3rd, McKinney, T. G., Schreiber, R. D. et al: Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol, 154: 6466, 1995
11. Chen, L., Chen, D., Block, E., O'Donnell, M., Kufe, D. W. and Clinton, S. K.: Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol, 159: 351, 1997
12. Eto, M., Harada, M., Tamada, K., Tokuda, N., Koikawa, Y., Nakamura, M. et al: Antitumor activity of interleukin-12 against murine bladder cancer. J Urol, 163: 1549, 2000
13. Kadhim, S. A., Chin, J. L., Batislam, E., Karlik, S. J., Garcia, B. and Skamene, E.: Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor. J Urol, 158: 646, 1997
14. Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchman, L. J., Larsen, G., Atkins, M. B. et al: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood, 90: 2541, 1997
15. Redlinger, R. E., Jr., Shimizu, T., Remy, T., Alber, S., Watkins, S. C. and Barksdale, E. M., Jr.: Cellular mechanisms of interleukin-12-mediated neuroblastoma regression. J Pediatr Surg, 38: 199, 2003
16. Zou, J. P., Yamamoto, N., Fujii, T., Takenaka, H., Kobayashi, M., Hermann, S. H. et al: Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol, 7: 1135, 1995
17. Kaempfer, R., Gerez, L., Farbstein, H., Madar, L., Hirschman, O., Nussinovich, R. et al: Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol, 14: 1778, 1996
18. Hill, L. L., Perussia, B., McCue, P. A. and Korngold, R.: Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency. Cancer Res, 54: 763, 1994
19. Wigginton, J. M., Komschlies, K. L., Back, T. C., Franco, J. L., Brunda, M. J. and Wiltrout, R. H.: Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst, 88: 38, 1996
20. Tanaka, M., Saijo, Y., Sato, G., Suzuki, T., Tazawa, R., Satoh, K. et al: Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma. Cancer Gene Ther, 7: 1481, 2000
21. Pappo, I., Tahara, H., Robbins, P. D., Gately, M. K., Wolf, S. F., Barnea, A. et al: Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy. J Surg Res, 58: 218, 1995